The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds
Graphical abstract
Section snippets
Acknowledgements
We thank University of North Carolina Psychoactive Drug Screening Program (PDSP) supported by NIMH for the receptor binding studies.
References and notes (33)
- et al.
Eur. J. Pharmacol.
(2012) - et al.
Pharmacol., Biochem. Behav.
(2011) - et al.
Pharmacol., Biochem. Behav.
(2012) - et al.
Pain
(2010) - et al.
Bioorg. Med. Chem.
(2003) - et al.
Bioorg. Med. Chem. Lett.
(2010) - et al.
Bioorg. Med. Chem. Lett.
(2009) - et al.
Tetrahedron
(2005) - et al.
Pain
(2009) - et al.
Chem. Rev.
(2008)
Nature
J. Neurochem.
PLoS ONE
Curr. Top. Med. Chem.
Int. Res. J. Pharm.
Cited by (19)
DDD-028: A potent, neuroprotective, non-opioid compound for the treatment of diabetic neuropathy
2023, Bioorganic and Medicinal Chemistry LettersN-Nitroso As A Novel Directing Group in Transition-Metal-Catalyzed C(sp<sup>2</sup>)−H Bond Functionalizations of N-Nitrosoanilines
2021, Asian Journal of Organic ChemistryRecent Advances in the Synthesis of Heterocyclics via Cascade Cyclization of Propargylic Alcohols
2021, Advanced Synthesis and CatalysisRecent developments on synthesis and biological activities of γ-carboline
2018, European Journal of Medicinal ChemistryCitation Excerpt :The latest research on these receptors has clearly defined the key roles that 5-HT2B plays in psychostimulant addiction through the modulation of dopamine release in the reward/pleasure centers in the brain, 5-HT6 in cognition, and 5-HT7 in both nociceptive and neuropathic pain via the descending serotonergic pathway. In 2014, Rajagopalan's group reported two compounds (169 and 170) that are highly selective ligands having moderate affinities to 5-HT7 and 5-HT2B and which play critical roles in neuropathic pain and psychostimulant addiction (Fig. 22) [65]. In 1989, it was reported that treatment of schizophrenic patients with the 5-HT2 receptor antagonist haloperidol in combination with the dopamine (D) 2 receptor antagonist ritanserin was found to help alleviate both the negative and positive symptoms of the disease, with a concomitant reduction in adverse movement disorders [66].
Recent advances in the tandem reaction of azides with alkynes or alkynols
2016, Organic and Biomolecular ChemistryDDD-028: A potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain
2014, Bioorganic and Medicinal Chemistry Letters